AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

Rentschler taps biopharma vet to lead ops. Rentschler Biopharma, the German CDMO with offices in Massachusetts and Stevenage, ...

In order to discuss this topic further, pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata ...

The analysis – reported at the European Association of Urology (EAU) annual congress in London, UK – shows that it is "no longer rational to reject prostate cancer screening on one hand while ...

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are ...

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD). Extending the label for Kerendia is a strategic priority for ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory tract disease caused ​by the virus, having previously been cleared for the ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with ...

They are due to leave by the end of this year to set up an as-yet unnamed "independent biotechnology company to research and ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...